Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

Marie José Kersten*, Julia Driessen, Josée M. Zijlstra, Wouter J. Plattel, Franck Morschhauser, Elly Lugtenburg, Pauline Brice, Martin Hutchings, Thomas Gastinne, Roberto D. Liu, Coreline N. Burggraaff, Marcel Nijland, Sanne H. Tonino, A. I.J. Arens, Roelf Valkema, Harm van Tinteren, Marta Lopez Yurda, Arjan Diepstra, Daphne de Jong, A (Anton) Hagenbeek

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

57 Citations (Scopus)
28 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology